St. Jude study identifies improved diagnostic test that benefits children with acute myeloid leukemia
Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research led by St. Jude Children’s Research Hospital investigators has identified the best test for measuring that response and guiding therapy. The method uses a laboratory technique called flow cytometry, which makes it possible to identify a single cancer cell in 1,000 normal cells that remain in patient bone marrow after the initial intensive weeks of chemotherapy.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.